Clinical Trials Logo

Clinical Trial Summary

The goal of this protocol is to evaluate the potential of PET imaging of amino acid transport and microglial activation to improve the differentiation of tumor recurrence and radiation necrosis in patients with brain metastases after treatment with stereotactic radiosurgery (SRS) who have re-growing lesions. These state-of-the-art imaging tools will be used in combination with standard magnetic resonance imaging (MRI), MR spectroscopy (MRS) and FDG-PET (fluorodeoxyglucose).


Clinical Trial Description

The investigators hypothesize that by using two different PET tracers, one sensitive to tumor metabolic activity, and one sensitive to inflammatory processes, investigators can separately identify metabolically active tumor from radiation necrosis related inflammation. This can be accomplished with quantitative assessments of tracer uptake using kinetic modeling techniques, as well as by high-resolution imaging to assess the distribution of tracer uptake in the tumor region. All participants in the study will have the receive the same diagnostic tests. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02433171
Study type Observational
Source Yale University
Contact
Status Terminated
Phase
Start date January 2015
Completion date June 27, 2017

See also
  Status Clinical Trial Phase
Withdrawn NCT01913067 - Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC Phase 2
Completed NCT02662725 - Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases Phase 2
Completed NCT00406835 - Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases Phase 3
Completed NCT01724801 - Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer Phase 3
Completed NCT00219297 - Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02328300 - FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
Terminated NCT01324635 - Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors Phase 1
Terminated NCT01894633 - Study of Whole-brain Irradiation With Chloroquine for Brain Metastases Phase 2
Recruiting NCT02681549 - Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Phase 2
Terminated NCT02279992 - Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases Early Phase 1
Completed NCT02913534 - Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy N/A
Completed NCT01942980 - Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer Phase 3
Terminated NCT01363557 - Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis N/A
Active, not recruiting NCT05102747 - Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation. N/A
Recruiting NCT01891708 - VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer N/A
Completed NCT01508221 - Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis Phase 2
Completed NCT00587964 - Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Phase 2
Not yet recruiting NCT06462079 - Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases Phase 2
Not yet recruiting NCT02832635 - A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases Phase 2
Completed NCT01395407 - Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases Phase 1